NCT05560802 Can the Use of a Next Generation Partograph Improve Neonatal Outcomes? (PICRINO)
| NCT ID | NCT05560802 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Linkoeping University |
| Condition | Neonatal Complication |
| Study Type | INTERVENTIONAL |
| Enrollment | 120,000 participants |
| Start Date | 2023-11-15 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120,000 participants in total. It began in 2023-11-15 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall aim is to evaluate the impact of the use of two different guidelines for monitoring labor progress, the WHOs LCG versus standard care, on neonatal and maternal outcomes. The hypothesis is that the use of LCG will reduce adverse neonatal outcomes and decrease the number of intrapartum Cesarean sections compared with standard care. Secondly, other perinatal interventions and complications will be compared between the LCG and standard care groups, as well as economic considerations. This will be investigated using a multicenter, stepped-wedge cluster randomized trial design. In addition, the project will explore a series of quantitative and qualitative research questions to gain in-depth knowledge about experiences and perceptions about childbirth and the use of LCG. These research questions will be investigated using questionnaires, focus group and individual interviews with providers, partners and women that have gone through childbirth.
Eligibility Criteria
Inclusion Criteria: -All women in active labor Exclusion Criteria: -No exclusion criteria
Contact & Investigator
Marie Blomberg, Professor
PRINCIPAL INVESTIGATOR
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Frequently Asked Questions
Who can join the NCT05560802 clinical trial?
This trial is open to female participants only, studying Neonatal Complication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05560802 currently recruiting?
Yes, NCT05560802 is actively recruiting participants. Contact the research team at marie.blomberg@liu.se for enrollment information.
Where is the NCT05560802 trial being conducted?
This trial is being conducted at Eksjö, Sweden, Falun, Sweden, Gällivare, Sweden, Gothenburg, Sweden and 11 additional locations.
Who is sponsoring the NCT05560802 clinical trial?
NCT05560802 is sponsored by Linkoeping University. The principal investigator is Marie Blomberg, Professor at Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.. The trial plans to enroll 120,000 participants.